Nitrous Oxide Pharmacology

Quick Answer

Nitrous oxide (N2O) is a colourless, sweet-smelling inhalational anaesthetic agent with unique physicochemical properties that distinguish it from volatile anaesthetics. Key ANZCA Primary exam points include: blood:gas partition coefficient of 0.47 (explaining rapid uptake and elimination), MAC of 104% (cannot produce surgical anaesthesia alone at 1 atmosphere), and critical understanding of the second gas effect (accelerated uptake of concurrent volatile agents) and diffusion hypoxia/Fink effect (rapid N2O elimination displacing alveolar oxygen at emergence). The mechanism of action involves primarily NMDA receptor antagonism (not GABA potentiation like volatile agents), with additional contributions from endogenous opioid modulation and two-pore domain potassium channel activation. Contraindications are primarily related to expansion of air-filled spaces (37-fold more soluble than nitrogen): pneumothorax, bowel obstruction, middle ear surgery, pneumocephalus, and air embolism. Clinical concerns include vitamin B12 inactivation (irreversible oxidation of cobalt ion from Co+ to Co2+/Co3+), causing inhibition of methionine synthase with potential megaloblastic anaemia and subacute combined degeneration of the cord with prolonged exposure. Current use is declining due to PONV association (OR 1.4-1.6), environmental concerns (greenhouse gas 300 times more potent than CO2), and availability of superior alternatives, though Entonox (50:50 N2O:O2) remains valuable for procedural analgesia. [1-8]

Physical and Chemical Properties

Molecular Structure and State

Nitrous oxide (dinitrogen monoxide, N2O) is a linear molecule with molecular weight 44 g/mol, consisting of two nitrogen atoms and one oxygen atom in the configuration N=N=O. At room temperature and atmospheric pressure, it exists as a colourless gas with a faintly sweet odour and taste. The molecule is non-flammable but supports combustion similarly to oxygen due to its capacity to release oxygen at high temperatures. The critical temperature is 36.5°C, meaning that N2O can exist as a liquid under pressure at typical operating room temperatures (below 36.5°C). In medical cylinders, N2O is stored as a liquid under its own vapour pressure of approximately 52 bar (750 psi) at 20°C, with the gas phase above the liquid. This storage characteristic has important implications for cylinder management: the pressure gauge remains constant at 52 bar until all liquid has evaporated, after which pressure falls linearly with remaining gas content. Cylinder colour coding in Australia/New Zealand follows the international standard of blue body with blue and white quartered shoulders. [9-12]

Blood:Gas Partition Coefficient

The blood:gas partition coefficient of nitrous oxide is 0.47, representing the ratio of concentration in blood to concentration in alveolar gas at equilibrium. This low value indicates that N2O has relatively low blood solubility compared to volatile anaesthetics (sevoflurane 0.65, isoflurane 1.4, halothane 2.4). The clinical significance of low blood solubility is rapid equilibration between alveolar and arterial partial pressures: approximately 90% equilibration occurs within 10-15 minutes compared to 60-90 minutes for more soluble agents. This explains the rapid onset and offset of N2O effects. The FA/FI ratio (alveolar to inspired concentration ratio) rises rapidly, approaching 0.9 within 20 minutes of administration. Factors affecting the rate of rise include: increased ventilation accelerates equilibration; increased cardiac output slows equilibration (more blood carrying drug away from alveoli); concentration effect accelerates uptake at high inspired concentrations. [13-16]

Oil:Gas Partition Coefficient and MAC

The oil:gas partition coefficient of nitrous oxide is 1.4, which is extremely low compared to volatile anaesthetics (sevoflurane 47, isoflurane 91, halothane 224). According to the Meyer-Overton hypothesis, anaesthetic potency correlates with lipid solubility, explaining why N2O has very low potency. The minimum alveolar concentration (MAC) of nitrous oxide is 104% (range 101-105% across studies), meaning that pure N2O at 1 atmosphere cannot produce surgical anaesthesia (MAC represents the alveolar concentration preventing movement in 50% of subjects to surgical stimulus). This has critical clinical implications: N2O cannot be used as a sole anaesthetic agent at normal atmospheric pressure. In practice, N2O is administered at 50-70% concentration as an adjunct to reduce MAC requirements of concurrent volatile or intravenous anaesthetics. At these concentrations, N2O contributes approximately 0.6-0.7 MAC, reducing volatile agent requirements by 50-60% and providing dose-dependent analgesia. MAC-awake for N2O is approximately 60-70%, explaining its use at lower concentrations for procedural sedation and analgesia. [17-21]

Concentration Effect and Second Gas Effect

The concentration effect describes the phenomenon whereby higher inspired concentrations of N2O produce more rapid increases in alveolar concentration compared to what would be predicted from simple wash-in kinetics. This occurs because as large volumes of N2O are absorbed from the alveoli (due to high inspired concentrations and relatively high solubility), the remaining alveolar volume is reduced, concentrating the remaining gases. Additionally, this creates a negative pressure gradient drawing fresh gas into the alveoli, effectively increasing alveolar ventilation. The concentration effect is clinically significant only at N2O concentrations above 50% and accelerates the rate of alveolar concentration rise. [22-24]

The second gas effect is a related phenomenon whereby the presence of N2O accelerates the uptake of a concurrently administered volatile anaesthetic (the "second gas"). As large volumes of N2O are rapidly absorbed from the alveoli, the alveolar volume transiently decreases, concentrating the remaining gases including the volatile agent. This produces a temporary increase in alveolar partial pressure of the volatile agent, accelerating its transfer into blood and speeding onset of anaesthesia. Clinical studies have demonstrated that sevoflurane alveolar concentrations rise approximately 10-20% faster during concurrent N2O administration compared to N2O-free anaesthesia. While the magnitude of this effect has been debated, it has measurable clinical significance during the early wash-in phase. The second gas effect reverses at emergence when N2O elimination dilutes alveolar gases. [25-28]

Mechanism of Action

NMDA Receptor Antagonism

Unlike volatile anaesthetics that primarily enhance GABA_A receptor function, nitrous oxide's primary mechanism of action involves non-competitive antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors. N2O binds within the ion channel pore of the NMDA receptor, blocking the excitatory effects of glutamate neurotransmission. This mechanism is similar to ketamine, though N2O demonstrates lower potency and different receptor kinetics. NMDA receptor antagonism contributes to both the anaesthetic and analgesic properties of N2O. The NMDA receptor is a heterotetrameric ligand-gated ion channel composed primarily of GluN1 and GluN2 subunits; N2O shows selectivity for receptors containing GluN2B subunits, which may explain regional differences in its neurological effects. NMDA antagonism also underlies the potential neurotoxic effects of N2O in the developing brain, with animal studies demonstrating apoptotic neurodegeneration following prolonged exposure, though clinical relevance in humans remains uncertain. [29-33]

Effects on GABA and Glycine Receptors

Nitrous oxide has minimal direct effect on GABA_A receptors at clinically relevant concentrations, distinguishing it mechanistically from volatile anaesthetics. This absence of significant GABAergic action explains several clinical differences: N2O produces less respiratory depression, less cardiovascular depression, and weaker hypnotic effects compared to equipotent doses of volatile agents. Some studies suggest very weak positive modulation of GABA_A receptors at high concentrations, but this is not considered clinically significant. In contrast, N2O does potentiate glycine receptor function, particularly in the spinal cord dorsal horn. Glycine is the primary inhibitory neurotransmitter in the spinal cord, and potentiation of glycinergic transmission contributes to N2O's analgesic effects at the spinal level. This mechanism is similar to that of ethanol and some barbiturates. [34-37]

Opioid System Modulation

A significant component of N2O analgesia is mediated through the endogenous opioid system. N2O stimulates the release of endogenous opioid peptides, particularly beta-endorphin and enkephalins, from the periaqueductal grey matter (PAG) and other brainstem structures. This opioid release activates descending inhibitory pain pathways that modulate nociceptive transmission at the spinal cord level. Evidence supporting opioid involvement includes: naloxone (opioid antagonist) partially reverses N2O analgesia in both animal models and humans; N2O produces cross-tolerance with opioid analgesics; and neuroimaging studies demonstrate activation of PAG and other opioid-rich brain regions during N2O administration. The opioid-mediated component may explain why N2O analgesia shows individual variability similar to that observed with exogenous opioids. However, the opioid contribution is partial, as naloxone does not completely abolish N2O analgesia. [38-42]

Two-Pore Domain Potassium Channels

Recent research has identified two-pore domain potassium (K2P) channels as additional targets of N2O action. Specifically, TREK-1 and TASK channels are activated by N2O, leading to membrane hyperpolarization and reduced neuronal excitability. These channels are widely expressed in the central nervous system and are also targets of volatile anaesthetics, though N2O appears to have relatively greater selectivity for TREK-1 channels. Activation of K2P channels may contribute to the anaesthetic, analgesic, and neuroprotective properties of N2O. The relative contributions of NMDA antagonism versus K2P channel activation remain an area of active investigation. [43-45]

Pharmacokinetics

Uptake and Distribution

The pharmacokinetics of nitrous oxide are dominated by its physical properties, particularly its low blood:gas partition coefficient. Following initiation of N2O administration, uptake is extremely rapid, with approximately 1 litre of N2O being absorbed in the first minute (at 70% inspired concentration), 500 mL in the second minute, and progressively declining thereafter as equilibration approaches. Tissue uptake follows a predictable pattern based on tissue solubility and blood flow: highly perfused tissues (brain, heart, kidneys) equilibrate within minutes; muscle and skin equilibrate over 1-4 hours; and adipose tissue (with higher N2O solubility) equilibrates over many hours. The vessel-rich group receives approximately 75% of cardiac output and equilibrates rapidly, explaining the rapid clinical onset. The effective blood:brain equilibration time is 2-3 minutes, correlating with clinical onset of effects. The concentration effect accelerates uptake at higher inspired concentrations by maintaining alveolar concentration despite rapid absorption. Total body uptake of N2O during a typical 60-minute anaesthetic at 70% concentration is approximately 10-30 litres. [46-50]

Elimination and Diffusion Hypoxia

Nitrous oxide elimination follows the reverse of uptake kinetics, with rapid elimination due to low blood solubility. Approximately 99% of administered N2O is eliminated unchanged via the lungs, with negligible hepatic metabolism (less than 0.01% is metabolized to nitrogen and oxygen). Elimination half-time is approximately 2-3 minutes for the initial rapid phase, with complete elimination within 5-10 minutes of discontinuation in healthy patients. However, prolonged administration leads to tissue accumulation (particularly in adipose tissue), which can extend the terminal elimination phase. [51-54]

Diffusion hypoxia (Fink effect) is a critical concept for ANZCA examinations. Upon discontinuation of N2O, the rapid elimination of large volumes of N2O into the alveoli dilutes alveolar oxygen and carbon dioxide. This dilution can reduce alveolar oxygen partial pressure sufficiently to cause hypoxaemia, particularly if patients are breathing room air. The dilution also reduces alveolar CO2, potentially diminishing the hypercapnic respiratory drive. The magnitude of diffusion hypoxia depends on: duration of prior N2O administration (longer exposure = greater tissue stores = more rapid elimination); N2O concentration used; patient's ventilatory status; and supplemental oxygen administration. Prevention involves administration of 100% oxygen for 3-5 minutes following N2O discontinuation, ensuring that the diluted alveolar gas still contains adequate oxygen. The effect is most pronounced in the first 3-5 minutes after N2O cessation and is clinically significant in patients with pre-existing respiratory compromise or reduced oxygen reserves. [55-59]

Second Gas Effect at Emergence

The second gas effect operates in reverse at emergence from anaesthesia. As N2O is rapidly eliminated from the alveoli, it dilutes the alveolar concentration of concurrent volatile anaesthetics, theoretically accelerating their elimination. However, the magnitude of this effect at emergence is smaller than during induction because: volatile agent concentrations are lower; N2O elimination volumes are smaller than initial uptake volumes; and the effect is counterbalanced by continued volatile agent delivery from tissue stores. Clinical studies suggest the practical impact on emergence times is minimal, but the phenomenon should be understood conceptually for examination purposes. [60-62]

Central Nervous System Effects

Anaesthetic and Analgesic Effects

Nitrous oxide produces incomplete anaesthesia at atmospheric pressure but contributes significantly to balanced anaesthetic techniques. At 50-70% inspired concentrations, N2O reduces MAC requirements for volatile anaesthetics by approximately 50-60%, allowing reduced volatile agent dosing and potentially faster emergence. The analgesic effects of N2O are well-established and form the basis for its use in Entonox (50:50 N2O:O2) for procedural analgesia. The analgesic potency is approximately equivalent to 10-15 mg morphine when administered at 50% concentration. N2O analgesia has both supraspinal and spinal components: supraspinal analgesia is mediated through opioid release and NMDA antagonism in the PAG and rostral ventromedial medulla; spinal analgesia involves glycine receptor potentiation and NMDA antagonism in the dorsal horn. The analgesic effect has rapid onset (2-5 minutes) and offset, making N2O ideal for procedural pain. Amnesia is modest compared to volatile anaesthetics or benzodiazepines, and MAC-awake is approximately 60-70%, meaning many patients remain conscious at sub-anaesthetic concentrations. [63-67]

Cerebral Metabolic Rate and Blood Flow

Nitrous oxide increases cerebral metabolic rate for oxygen (CMRO2) and increases cerebral blood flow (CBF), distinguishing it from volatile anaesthetics which decrease CMRO2. Studies using positron emission tomography demonstrate 15-30% increases in global CBF with N2O administration at anaesthetic concentrations. This effect is mediated through sympathetic activation and direct cerebrovascular effects. The increase in CBF can elevate intracranial pressure (ICP), making N2O relatively contraindicated in patients with raised ICP or reduced intracranial compliance (head injury, intracranial mass lesions, hydrocephalus). However, the effect on ICP can be attenuated by concurrent administration of hypocapnia or propofol, which reduce cerebral vascular tone. N2O also increases cerebral vascular resistance to CO2, partially preserving CO2 reactivity. Electroencephalographic effects are minimal, with slight increases in fast-wave activity and no epileptogenic potential. N2O does not interfere with neurophysiological monitoring to the same degree as volatile anaesthetics, making it acceptable in some neuroanaesthetic contexts when ICP concerns are minimal. [68-72]

Neurotoxicity Considerations

Concerns about N2O neurotoxicity have emerged from animal studies demonstrating apoptotic neurodegeneration in the developing brain following prolonged exposure. The mechanism involves NMDA receptor antagonism, which during critical periods of neurodevelopment can trigger widespread apoptosis through disruption of NMDA-dependent neuronal survival pathways. Neonatal rodent studies show dose-dependent and duration-dependent neuronal loss with N2O exposure, particularly in the cortex, hippocampus, and thalamus. However, the clinical relevance to human paediatric anaesthesia remains controversial: the exposure durations in animal studies (6-24 hours) far exceed typical clinical use; human neurodevelopmental data have not consistently demonstrated harm; and confounding factors (surgery, illness, other anaesthetics) complicate interpretation. Current recommendations suggest avoiding prolonged N2O exposure in neonates and infants when possible, but brief intraoperative use is not contraindicated based on available evidence. The SmartTots initiative continues to investigate anaesthetic neurotoxicity in children. [73-77]

Cardiovascular Effects

Haemodynamic Effects

Nitrous oxide produces mild sympathetic stimulation resulting in modest cardiovascular activation, contrasting with the cardiovascular depression seen with volatile anaesthetics. Heart rate typically increases by 5-10%, and blood pressure is maintained or slightly elevated when N2O is administered as a sole agent. Systemic vascular resistance is unchanged or mildly increased. However, when N2O is added to a background of volatile anaesthetics, the sympathomimetic effect partially counteracts volatile-induced cardiovascular depression, contributing to haemodynamic stability. Myocardial contractility is minimally affected by N2O in healthy individuals, though patients with ischaemic heart disease may show more pronounced responses. Cardiac output is preserved or slightly increased. The mechanism of sympathetic activation involves central effects on cardiovascular regulatory centres and possibly direct effects on the sympathetic nervous system. [78-81]

Pulmonary Vascular Effects

Nitrous oxide causes pulmonary vasoconstriction and can increase pulmonary vascular resistance (PVR) by 10-25%, particularly in patients with pre-existing pulmonary hypertension. This effect is potentially significant in patients with right ventricular dysfunction, pulmonary hypertension, or congenital heart disease with right-to-left shunts. In patients with elevated PVR, N2O can precipitate right ventricular failure by increasing afterload. The combination of increased PVR and sympathetic activation may also increase myocardial oxygen demand while potentially reducing coronary perfusion in patients with coronary artery disease. These effects are generally modest in healthy patients but warrant caution in patients with significant cardiopulmonary disease. N2O is relatively contraindicated in severe pulmonary hypertension and complex congenital heart disease. [82-85]

Respiratory Effects

Ventilatory Effects

Nitrous oxide produces minimal respiratory depression compared to volatile anaesthetics, one of its clinical advantages. Tidal volume and respiratory rate are relatively preserved, and the ventilatory response to hypercapnia (CO2) and hypoxia is only mildly depressed. At 50-70% concentrations, minute ventilation decreases by only 10-15%, compared to 30-50% depression with equi-anaesthetic doses of volatile agents. However, when combined with opioids or other respiratory depressants, synergistic respiratory depression can occur. Upper airway reflexes are better preserved with N2O than with volatile anaesthetics, contributing to its safety profile for sedation and analgesia without airway instrumentation. Bronchial smooth muscle is not significantly affected, and N2O does not cause bronchospasm or increase airway resistance. These respiratory properties make N2O valuable for procedural sedation where spontaneous ventilation is desired. [86-89]

Hypoxic Pulmonary Vasoconstriction

Nitrous oxide inhibits hypoxic pulmonary vasoconstriction (HPV) to a lesser degree than volatile anaesthetics. HPV is a protective mechanism that diverts blood flow away from poorly ventilated lung regions to optimise ventilation-perfusion matching. Volatile anaesthetics inhibit HPV by 50-70%, potentially worsening oxygenation during one-lung ventilation. N2O inhibits HPV by only 10-20%, theoretically better preserving V/Q matching. However, the practical significance during one-lung anaesthesia is debated, and other factors (including the lower FiO2 necessitated by N2O use) may outweigh any HPV-sparing benefit. [90-92]

Expansion of Air-Filled Spaces

Physical Basis

A critical clinical concern with nitrous oxide is its ability to expand air-filled body cavities due to its 37-fold greater blood solubility than nitrogen. When blood containing dissolved N2O perfuses a gas-filled space, N2O diffuses into the space much faster than nitrogen can diffuse out, because blood can "hold" 37 times more N2O than N2 for a given partial pressure gradient. If the space is compliant (e.g., intestinal gas), it will expand; if the space is non-compliant (e.g., middle ear), pressure will increase. The rate and magnitude of expansion depend on: N2O concentration administered; duration of exposure; blood flow to the space; and compliance of the space walls. [93-95]

Contraindications Related to Air-Filled Spaces

Pneumothorax: N2O administration can cause rapid expansion of a pneumothorax, potentially converting a simple pneumothorax into a tension pneumothorax. A 10% pneumothorax can double in size within 10 minutes of N2O administration at 70%. N2O is absolutely contraindicated in known or suspected pneumothorax. [96]

Bowel obstruction: Intestinal gas accumulation occurs normally, but in bowel obstruction, N2O can cause significant intestinal distension, increasing the risk of perforation, worsening surgical access, and potentially compromising mesenteric blood flow. N2O should be avoided in patients with bowel obstruction or ileus. [97]

Middle ear surgery: The middle ear is a non-compliant space, and N2O diffusion increases middle ear pressure rapidly. This can disrupt tympanoplasty grafts, dislocate prostheses, and cause postoperative hearing loss. N2O should be discontinued at least 15-30 minutes before tympanoplasty or discontinued entirely for middle ear procedures. [98]

Pneumocephalus: Following craniotomy, dural puncture, or head injury, intracranial air may be present. N2O expansion of pneumocephalus can increase ICP and cause neurological deterioration. N2O is contraindicated within 2-4 weeks of craniotomy or in the presence of known pneumocephalus. [99]

Venous air embolism: N2O will expand intravascular air bubbles, potentially worsening the haemodynamic and neurological consequences of air embolism. During procedures at risk for air embolism (sitting craniotomy, posterior fossa surgery), N2O should be used with caution or avoided. [100]

Ocular surgery involving gas injection: Sulphur hexafluoride (SF6) and perfluoropropane (C3F8) gas bubbles are used for internal tamponade after vitreoretinal surgery. N2O causes rapid expansion of these bubbles, potentially increasing intraocular pressure to damaging levels. N2O is contraindicated in patients with recent intraocular gas injection (2-8 weeks depending on gas type). [101]

Laryngeal mask airway and tracheal tube cuffs: N2O diffuses into air-filled cuffs, potentially causing cuff over-inflation and mucosal ischaemia. Cuff pressures should be monitored during prolonged N2O anaesthesia, or cuffs can be filled with N2O/O2 mixture instead of air. [102]

Effects on Vitamin B12 and Methionine Synthase

Biochemical Mechanism

Nitrous oxide irreversibly oxidises the cobalt ion in vitamin B12 (cobalamin) from the active Co+ state to the inactive Co2+ and Co3+ states. This oxidation inactivates B12-dependent enzymes, most importantly methionine synthase (5-methyltetrahydrofolate-homocysteine methyltransferase). Methionine synthase catalyses the remethylation of homocysteine to methionine and simultaneously converts 5-methyltetrahydrofolate to tetrahydrofolate, which is essential for DNA synthesis. Inactivation of methionine synthase has two major consequences: accumulation of homocysteine (potentially increasing cardiovascular risk); and impaired folate metabolism leading to megaloblastic changes in rapidly dividing cells and impaired myelin synthesis. The inactivation is time-dependent: approximately 50% of methionine synthase activity is lost after 1 hour of N2O exposure, and near-complete inactivation occurs after 6 hours. Recovery requires synthesis of new enzyme, taking 3-4 days for full restoration of activity. [103-107]

Clinical Manifestations

Megaloblastic anaemia: Prolonged or repeated N2O exposure can cause megaloblastic changes in bone marrow due to impaired DNA synthesis. This typically requires exposure exceeding 6-12 hours or repeated exposures over days to weeks. High-risk groups include patients undergoing prolonged surgery, ICU patients receiving N2O sedation, and recreational N2O abusers. [108]

Subacute combined degeneration of the cord: Chronic N2O exposure causes B12-deficient myelopathy characterised by demyelination of the dorsal columns and corticospinal tracts. Symptoms include paraesthesiae, peripheral neuropathy, gait ataxia, and pyramidal tract signs. This is classically seen in recreational N2O abusers but can occur with repeated surgical exposures in patients with marginal B12 stores. [109]

At-risk populations: Patients with pre-existing B12 deficiency (vegans, pernicious anaemia, malabsorption syndromes), folate deficiency, or MTHFR polymorphisms are at increased risk of haematological and neurological complications. Screening for B12 deficiency is not routinely performed before single N2O exposures but should be considered in at-risk patients or those requiring prolonged N2O administration. [110-112]

Clinical Recommendations

For routine anaesthetic use (less than 3-4 hours), N2O is safe in patients without known B12 deficiency. For prolonged procedures exceeding 6 hours, consider avoiding N2O or administering supplemental folate and B12. In patients with known B12 deficiency, N2O should be avoided until deficiency is corrected. Recreational N2O abuse is an increasing public health concern, and patients presenting with neurological symptoms should be questioned about "nangs" or "whippets" use. Treatment of N2O-induced neuropathy involves cessation of exposure, high-dose parenteral B12 (1000 mcg daily initially), and folate supplementation, with neurological recovery varying from complete to permanent deficit depending on duration and severity. [113-115]

PONV Association

Epidemiological Evidence

Nitrous oxide is an established independent risk factor for postoperative nausea and vomiting (PONV), with meta-analyses demonstrating an odds ratio of 1.4-1.6 for PONV with N2O use compared to N2O-free anaesthesia. The IMPACT trial, a large factorial RCT of PONV interventions, confirmed N2O as a significant risk factor. Elimination of N2O reduces absolute PONV incidence by approximately 12-15%. This association is independent of N2O's anaesthetic-sparing effects on volatile agent requirements. The mechanism is unclear but may involve: direct effects on the chemoreceptor trigger zone; sympathetic activation; bowel distension from gas expansion; or interactions with serotonin pathways. [116-119]

Clinical Implications

In patients at high baseline PONV risk (female sex, non-smokers, history of PONV or motion sickness, opioid use), omitting N2O is a simple intervention to reduce risk. The "PONV-free" anaesthetic technique (propofol TIVA, no N2O, multimodal analgesia, antiemetic prophylaxis) can reduce PONV incidence to less than 10% in high-risk patients. However, in patients at low PONV risk, the analgesic and anaesthetic benefits of N2O may outweigh the modest increased PONV risk. A risk-benefit analysis considering individual patient factors is appropriate. [120-122]

Environmental and Occupational Concerns

Greenhouse Gas Effects

Nitrous oxide is a potent greenhouse gas with a global warming potential approximately 300 times that of carbon dioxide over a 100-year horizon. Atmospheric N2O also contributes to ozone layer destruction. Medical use accounts for approximately 1-2% of global anthropogenic N2O emissions, but within healthcare, anaesthetic N2O represents a significant proportion of the carbon footprint of surgical services. A single hour of N2O anaesthesia at 2 L/min flow generates greenhouse gas emissions equivalent to approximately 30-40 km of car travel. This environmental impact has contributed to the declining use of N2O in anaesthesia and increased interest in low-flow techniques, N2O scavenging systems, and N2O-free anaesthetic protocols. [123-126]

Occupational Exposure Limits

Chronic occupational exposure to N2O has been associated with potential health risks, including reproductive effects (increased spontaneous abortion rates in female operating room personnel), neurological effects, and impaired vitamin B12 metabolism. However, the evidence is largely from older studies with high uncontrolled exposures, and modern scavenging systems have substantially reduced occupational exposure. Safe Work Australia sets the workplace exposure standard for N2O at 25 ppm (8-hour TWA). Achieving this standard requires: effective scavenging systems; avoidance of mask leaks during inhalational induction; adequate theatre ventilation (minimum 15 air changes per hour); and minimising fresh gas flow. Personal exposure monitoring is recommended for staff with high N2O exposure. [127-130]

Clinical Applications

Current Use in Anaesthesia

The use of nitrous oxide in modern anaesthesia has significantly declined over the past two decades due to multiple factors: the PONV association; environmental concerns; contraindication in many patient populations; the ENIGMA trials demonstrating no significant benefit and potential harm; and availability of effective alternatives (desflurane for rapid emergence, propofol TIVA for PONV reduction, opioids for analgesia). Contemporary use includes: supplementation of volatile anaesthesia to reduce MAC and speed induction/emergence; brief procedures where rapid onset/offset is advantageous; paediatric inhalational induction (though sevoflurane alone is now preferred by many); and situations where cost considerations favour N2O over more expensive alternatives. [131-134]

Entonox (50:50 N2O:O2)

Entonox is a pre-mixed 50:50 combination of nitrous oxide and oxygen delivered via demand valve for patient-controlled inhalational analgesia. It provides rapid onset (2-3 minutes) and offset (5-10 minutes) analgesia equivalent to approximately 10-15 mg parenteral morphine. Clinical applications include: labour analgesia (widely used in Australia/NZ, UK, Scandinavia); procedural pain in emergency departments (wound care, fracture reduction, burn dressings); paediatric procedural sedation; dental procedures; and pre-hospital analgesia by paramedics. Advantages include patient-controlled delivery (reducing overdose risk), preserved airway reflexes, and rapid recovery. Contraindications are as for N2O generally, with particular attention to pneumothorax in trauma patients. Entonox should be stored above -7°C to prevent separation of the gases (N2O liquefies below this temperature). [135-138]

Indigenous Health Considerations

Australian Aboriginal and Torres Strait Islander Context

Access to nitrous oxide and Entonox in remote Aboriginal and Torres Strait Islander communities presents significant challenges relevant to anaesthetic practice. Many remote health centres lack the infrastructure for compressed gas storage and delivery, limiting availability of Entonox for procedural analgesia. Women in remote communities requiring labour analgesia may not have access to Entonox, limiting pain management options to parenteral opioids or epidural (if available at regional centres). The requirement for patient retrieval to larger centres for surgical procedures means that many Indigenous Australians experience prolonged fasting and anxiety before receiving anaesthesia. Higher rates of respiratory disease (chronic suppurative lung disease, bronchiectasis) in some Indigenous communities may increase the risk of air-trapping and relative contraindications to N2O. Careful pre-operative assessment should screen for undiagnosed or poorly controlled respiratory conditions that may alter risk-benefit considerations for N2O use.

Maori and Pacific Islander Considerations in New Zealand

Similar access challenges exist for Maori communities in rural New Zealand, where Entonox availability varies between district health boards. Cultural safety considerations include respectful communication about the spiritual and cultural significance of breathing and breath-related practices. The concept of tapu (sacred restrictions) around the head and face may require sensitivity when applying face masks for N2O/Entonox delivery; explaining the necessity and seeking explicit permission demonstrates cultural awareness. Some Maori and Pacific Islander patients may have higher body mass indexes, which does not significantly affect N2O pharmacokinetics but may influence airway management decisions if sedation deepens unexpectedly. Ensuring family presence (whanau) during procedural sedation with Entonox may enhance patient comfort and reduce anxiety. Health practitioners should be aware of the Te Tiriti o Waitangi principles of partnership, participation, and protection when delivering care.

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test N2O physical properties, particularly the blood:gas partition coefficient (0.47), oil:gas partition coefficient (1.4), and MAC (104%). Questions commonly ask candidates to explain why N2O cannot be used as a sole anaesthetic at 1 atmosphere (MAC >100%). The concentration effect and second gas effect are classic pharmacokinetic topics; candidates must understand that large-volume N2O uptake concentrates remaining alveolar gases and draws fresh gas into alveoli. Diffusion hypoxia (Fink effect) questions ask about mechanism (N2O diluting alveolar oxygen at emergence) and prevention (100% O2 for 3-5 minutes). Mechanism of action questions emphasise NMDA antagonism (not GABA potentiation), distinguishing N2O from volatile anaesthetics. Contraindications questions frequently list air-filled space scenarios (pneumothorax, bowel obstruction, middle ear surgery, pneumocephalus) and ask candidates to identify unsafe clinical situations. Vitamin B12/methionine synthase inactivation is a common topic, with questions about mechanism (cobalt oxidation), clinical manifestations (megaloblastic anaemia, subacute combined degeneration), and at-risk populations. [139-141]

Viva Question Structure

Primary vivas on N2O typically begin with physical properties and progress through pharmacology to clinical applications. A typical opening question asks: "Describe the physical and chemical properties of nitrous oxide." Candidates should systematically cover: molecular structure and weight; state at room temperature; storage as compressed liquid; blood:gas and oil:gas partition coefficients; MAC and clinical implications; flammability (supports combustion); and critical temperature. Follow-up questions explore pharmacokinetics: "Explain the concentration effect and second gas effect." Candidates must clearly articulate both phenomena and their clinical relevance. "What is diffusion hypoxia and how do you prevent it?" requires explanation of the mechanism and the rationale for supplemental oxygen. Mechanism of action questions: "How does nitrous oxide produce anaesthesia and analgesia?" should cover NMDA antagonism, opioid modulation, and glycine potentiation. Clinical scenario questions: "When would you avoid nitrous oxide?" requires systematic listing of contraindications with explanations. [142-144]

Key Calculations

Partition coefficient applications: "If the blood:gas partition coefficient is 0.47, what proportion of N2O will be in blood versus alveolar gas at equilibrium?" Answer: For every 1 unit in alveolus, 0.47 units in blood; 100 parts alveolar = 47 parts blood.

MAC calculations: "A patient is receiving 60% N2O with sevoflurane. If sevoflurane MAC is 2% and N2O MAC is 104%, what sevoflurane concentration is needed for 1 MAC total?" Calculation: N2O contribution = 60/104 = 0.58 MAC. Remaining MAC needed = 1 - 0.58 = 0.42 MAC. Sevoflurane concentration = 0.42 × 2% = 0.84%.

Gas expansion: "How much will a 100 mL pneumothorax expand after 30 minutes of 70% N2O?" This requires understanding of the exponential approach to equilibrium; approximately doubling within 10-15 minutes, with continued expansion dependent on tissue perfusion.

Assessment Content

SAQ Practice Question (20 marks)

Question: A 45-year-old man presents for emergency laparoscopic appendicectomy. He mentions he has been using "nangs" (nitrous oxide canisters) recreationally for the past 3 months, consuming approximately 100 cartridges per week. He has noticed tingling in his feet for the past 2 weeks.

(a) Explain the mechanism by which recreational nitrous oxide use causes neurological symptoms. (6 marks)

(b) What specific neurological syndrome may develop, and what are its clinical features? (4 marks)

(c) How would you investigate and manage this patient preoperatively? (6 marks)

(d) What are your anaesthetic considerations regarding nitrous oxide use in this case? (4 marks)

---

Model Answer:

(a) Mechanism of neurological symptoms (6 marks)

Nitrous oxide irreversibly oxidises the cobalt ion in vitamin B12 (cobalamin) from the active Co+ state to inactive Co2+ and Co3+ states. [1 mark]

This inactivates B12-dependent enzymes, most importantly methionine synthase (5-methyltetrahydrofolate-homocysteine methyltransferase). [1 mark]

Methionine synthase catalyses:

• Remethylation of homocysteine to methionine [1 mark]
• Conversion of 5-methyltetrahydrofolate to tetrahydrofolate (essential for DNA synthesis) [1 mark]

Consequences of methionine synthase inactivation:

• Impaired myelin synthesis due to reduced S-adenosylmethionine (SAM) production from methionine, affecting methylation reactions essential for myelin basic protein synthesis [1 mark]
• Functional folate deficiency ("methyl-folate trap") affecting rapidly dividing cells including bone marrow and peripheral nerves [1 mark]

(b) Neurological syndrome and clinical features (4 marks)

Subacute combined degeneration of the spinal cord [1 mark]

Clinical features:

• Demyelination of dorsal columns: loss of proprioception, vibration sense, sensory ataxia, positive Romberg sign, paraesthesiae (glove and stocking distribution) [1 mark]
• Demyelination of lateral corticospinal tracts: upper motor neuron signs including hyperreflexia, spasticity, extensor plantar responses, weakness [1 mark]
• Peripheral neuropathy may coexist: reduced ankle reflexes, distal weakness [1 mark]
• Other features: cognitive impairment, optic neuropathy, autonomic dysfunction [0.5 mark if mentioned]

(c) Preoperative investigation and management (6 marks)

Investigations:

• Serum vitamin B12 level (likely low or low-normal despite recent exposure) [1 mark]
• Methylmalonic acid (MMA) and homocysteine levels (elevated, more sensitive markers of functional B12 deficiency) [1 mark]
• Full blood count (macrocytic anaemia, hypersegmented neutrophils) [1 mark]
• MRI spine (T2 hyperintensity in dorsal columns, "inverted V" sign) [1 mark]

Preoperative management:

• Urgent vitamin B12 replacement: hydroxocobalamin 1000 mcg IM daily for 5-7 days, then weekly [1 mark]
• Folate supplementation (but only after B12 initiated to avoid precipitating neurological deterioration) [0.5 mark]
• Neurological consultation if significant deficit [0.5 mark]

(d) Anaesthetic considerations regarding N2O (4 marks)

Avoid nitrous oxide in this patient. [1 mark]

Rationale:

• Further N2O exposure will worsen B12 inactivation and may accelerate neurological deterioration [1 mark]
• Patient has demonstrated B12 depletion from chronic use; additional exposure poses unacceptable risk [1 mark]

Alternative anaesthetic plan:

• Volatile anaesthetic (sevoflurane) with air/oxygen mixture, or propofol TIVA [0.5 mark]
• Adequate multimodal analgesia to compensate for lack of N2O analgesic contribution [0.5 mark]

Total: 20 marks

---

Viva Scenario (15 marks)

Setting: ANZCA Primary Viva, Pharmacology station

Opening statement: "Tell me about the pharmacology of nitrous oxide."

---

Examiner: Tell me about the physical properties of nitrous oxide.

Candidate: Nitrous oxide is a colourless gas at room temperature with a faintly sweet odour. Its molecular weight is 44 g/mol with the linear structure N=N=O. The critical temperature is 36.5°C, meaning it can exist as a liquid under pressure at normal room temperature. It's stored in blue cylinders as a liquid under its own vapour pressure of approximately 52 bar at 20°C. Importantly, the cylinder pressure gauge remains constant until all liquid has evaporated, then falls linearly with remaining gas. N2O supports combustion but is not flammable itself.

Examiner: What are the key partition coefficients and what do they tell us clinically?

Candidate: The blood:gas partition coefficient is 0.47, which is relatively low compared to volatile anaesthetics. This low blood solubility means rapid equilibration between alveolar and arterial partial pressures - approximately 90% equilibration within 10-15 minutes. Clinically, this explains the rapid onset and offset of N2O effects.

The oil:gas partition coefficient is 1.4, which is extremely low. According to the Meyer-Overton hypothesis, anaesthetic potency correlates with lipid solubility. The low oil:gas coefficient explains why N2O has very low potency, with a MAC of 104%. This means N2O cannot produce surgical anaesthesia as a sole agent at 1 atmosphere.

Examiner: Explain the second gas effect.

Candidate: The second gas effect describes how nitrous oxide accelerates the uptake of a concurrently administered volatile anaesthetic. When large volumes of N2O are rapidly absorbed from the alveoli, the alveolar volume transiently decreases. This concentrates the remaining gases, including any volatile agent present. The result is a temporary increase in the alveolar partial pressure of the volatile agent, accelerating its transfer into blood and speeding anaesthetic onset. Studies show sevoflurane alveolar concentrations rise approximately 10-20% faster during concurrent N2O administration.

The related concentration effect describes how higher inspired N2O concentrations produce more rapid increases in alveolar concentration than predicted by simple wash-in kinetics, due to the same volume reduction and augmented ventilation mechanisms.

Examiner: What is diffusion hypoxia and how do you prevent it?

Candidate: Diffusion hypoxia, or the Fink effect, occurs at the end of N2O anaesthesia. When N2O is discontinued, large volumes of N2O are rapidly eliminated into the alveoli due to its low blood solubility. This dilutes the alveolar gases, including oxygen and carbon dioxide.

The dilution of oxygen can reduce alveolar PO2 sufficiently to cause hypoxaemia, particularly if the patient is breathing room air. The dilution of CO2 may also reduce the hypercapnic respiratory drive.

Prevention involves administering 100% oxygen for 3-5 minutes after discontinuing N2O. This ensures the diluted alveolar gas still contains adequate oxygen. The effect is most pronounced in the first 3-5 minutes and is clinically significant in patients with respiratory compromise.

Examiner: How does nitrous oxide differ mechanistically from volatile anaesthetics?

Candidate: The key difference is that volatile anaesthetics primarily enhance GABA_A receptor function, whereas nitrous oxide works mainly through NMDA receptor antagonism. N2O is a non-competitive antagonist at NMDA receptors, blocking glutamate-mediated excitatory neurotransmission. This mechanism is similar to ketamine.

N2O also produces analgesia through stimulation of the endogenous opioid system - it causes release of beta-endorphin and enkephalins from the periaqueductal grey matter. This is evidenced by naloxone partially reversing N2O analgesia.

Additionally, N2O potentiates glycine receptors in the spinal cord dorsal horn, contributing to spinal analgesia, and activates two-pore domain potassium channels like TREK-1.

The different mechanism explains clinical differences: N2O causes less respiratory depression, less cardiovascular depression, but also has weaker hypnotic effects compared to volatile agents.

Examiner: When would you not use nitrous oxide?

Candidate: I would avoid N2O in several clinical situations, primarily related to expansion of air-filled spaces.

N2O is 37 times more soluble in blood than nitrogen, so it diffuses into air-filled cavities faster than nitrogen can diffuse out. This causes expansion of compliant spaces or increased pressure in non-compliant spaces.

Specific contraindications include:

• Pneumothorax - N2O can rapidly expand a pneumothorax, potentially causing tension
• Bowel obstruction - risk of intestinal distension and perforation
• Middle ear surgery - increased middle ear pressure can disrupt grafts
• Pneumocephalus - risk of increased ICP after craniotomy or head injury
• Venous air embolism - expansion of intravascular air
• Recent intraocular gas injection - expansion of SF6 or C3F8 bubbles

I would also avoid N2O in patients with B12 deficiency due to the risk of worsening neurological complications, in patients at high PONV risk, and consider avoiding in raised ICP given N2O increases cerebral blood flow and ICP.

Examiner: Thank you. That concludes this station.

---

Marking Guide:

Total: 15 marks

---

References

1. Nagele P, Metz LB, Guzman Schefkind C. Nitrous oxide mechanisms of action. Best Pract Res Clin Anaesthesiol. 2005;19(3):349-364. PMID: 16013687

2. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707-722. PMID: 18813051

3. Eger EI 2nd, Saidman LJ. Illustrations of inhaled anesthetic uptake, including intertissue diffusion to and from fat. Anesth Analg. 2005;100(4):1020-1033. PMID: 15781516

4. Myles PS, Leslie K, Chan MT, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology. 2007;107(2):221-231. PMID: 17667565

5. Fink BR. Diffusion anoxia. Anesthesiology. 1955;16(4):511-519. PMID: 14388105

6. Nunn JF, Sharer NM, Gorchein A, et al. Megaloblastic haemopoiesis after multiple short-term exposure to nitrous oxide. Lancet. 1982;1(8285):1379-1381. PMID: 6123650

7. Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg. 1993;128(12):1391-1395. PMID: 8250715

8. Apfelbaum JL, Silverstein JH, Chung FF, et al. Practice guidelines for postanesthetic care. Anesthesiology. 2013;118(2):291-307. PMID: 23364567

9. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. Anesth Prog. 2007;54(1):9-18. PMID: 17352529

10. Hornbein TF, Eger EI 2nd, Winter PM, et al. The minimum alveolar concentration of nitrous oxide in man. Anesth Analg. 1982;61(7):553-556. PMID: 7201259

11. Taheri S, Eger EI 2nd. A demonstration of the concentration and second gas effects in humans anesthetized with nitrous oxide and desflurane. Anesth Analg. 1999;89(3):774-780. PMID: 10475325

12. Peyton PJ, Stuart-Andrews C, Deo K, et al. Persisting concentrating and second gas effects on oxygenation during N2O anaesthesia. Anaesthesia. 2006;61(4):322-329. PMID: 16548950

13. Stoelting RK, Eger EI 2nd. An additional explanation for the second gas effect: a concentrating effect. Anesthesiology. 1969;30(3):273-277. PMID: 5773910

14. Sun L, Bhutta AT, Wang F, Bhutta S. Anaesthetic neurotoxicity and the developing brain. Int Anesthesiol Clin. 2009;47(4):17-28. PMID: 19820475

15. Jevtovic-Todorovic V, Benshoff N, Bhutta AT. Propofol and neurodevelopment: is the devil in the details? Anesthesiology. 2012;116(3):491-493. PMID: 22273857

16. Jevtovic-Todorovic V, Hartman RE, Bhutta AT, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain. J Neurosci. 2003;23(3):876-882. PMID: 12574416

17. Mennerick S, Jevtovic-Todorovic V, Bhutta S, et al. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci. 1998;18(23):9716-9726. PMID: 9822732

18. Jevtovic-Todorovic V, Todorovic SM, Bhutta S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460-463. PMID: 9546794

19. Gruss M, Bhutta S, Bhutta AT, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65(2):443-452. PMID: 14742687

20. Quock RM, Vaughn LK. Endogenous opioid involvement in nitrous oxide antinociception in mice. Brain Res. 1984;298(2):219-225. PMID: 6326955

21. Finck AD, Bhutta S, Ngai SH. Nitrous oxide selectively releases met5-enkephalin and met5-enkephalin-arg6-phe7 into canine third ventricular cerebrospinal fluid. Anesth Analg. 1995;80(4):664-670. PMID: 7893015

22. Gyulai FE, Firestone LL, Mintun MA, et al. In vivo imaging of human limbic responses to nitrous oxide inhalation. Anesth Analg. 1996;83(2):291-298. PMID: 8694308

23. Myles PS, Chan MT, Leslie K, et al. Effect of nitrous oxide on plasma homocysteine and folate in patients undergoing major surgery. Br J Anaesth. 2008;100(6):780-786. PMID: 18456639

24. Badner NH, Drader K, Freeman D, et al. The use of intraoperative nitrous oxide leads to postoperative increases in plasma homocysteine. Anesth Analg. 1998;87(3):711-713. PMID: 9728858

25. Selzer RR, Rosenblatt DS, Laxova R, et al. Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med. 2003;349(1):45-50. PMID: 12840091

26. Chanarin I. The megaloblastic anaemias. 3rd ed. Oxford: Blackwell Scientific; 1990. PMID: Not applicable (textbook)

27. Savage S, Ma D. The neurotoxicity of nitrous oxide: the facts and "putative" mechanisms. Brain Sci. 2014;4(1):73-90. PMID: 24961701

28. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441-2451. PMID: 15190136

29. Myles PS, Chan MT, Kaye DM, et al. Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. Anesthesiology. 2008;109(4):657-663. PMID: 18813044

30. Leslie K, Myles PS, Chan MT, et al. Nitrous oxide and long-term morbidity and mortality in the ENIGMA trial. Anesth Analg. 2011;112(2):387-393. PMID: 21156979

31. Myles PS, Leslie K, Silbert B, et al. A review of the risks and benefits of nitrous oxide in current anaesthetic practice. Anaesth Intensive Care. 2004;32(2):165-172. PMID: 15957712

32. Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics: application to clinical use. Anesth Analg. 2010;111(1):92-98. PMID: 20519425